Drug Profile


Alternative Names: EMD-68843; SB-659746A; Viibryd; Vilazodone hydrochloride

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck KGaA
  • Developer Allergan; moksha8 Pharmaceuticals
  • Class Amides; Antidepressants; Benzofurans; Indoles; Nitriles; Piperazines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase III Generalised anxiety disorder
  • Phase II Social phobia
  • No development reported Sexual function disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Sexual-function-disorders(In volunteers) in USA (PO, Tablet)
  • 01 Oct 2016 Forest Laboratories completes a phase III trial for Major depressive disorder (in adolescents) in USA (NCT01878292)
  • 01 Apr 2015 Forest initiates enrolment in a phase III trial for Major depressive disorder (In children, In adolescents, aged 7-17 years) in USA (NCT02436239)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top